• Explore /
  • Poster
  • / Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).

Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).

Abstract Poster

Authors

null

Xianjun Yu

Fudan University Shanghai Cancer Center, Shanghai, China

Xianjun Yu , Jianming Xu , Lin Shen , Chunmei Bai , Jie Li , Zhiwei Zhou , Zhiping Li , Enxiao LI , Xianglin Yuan , Yihebali Chi , Yongmei Yin , Wenhui Lou , Nong Xu , Yuxian Bai , Tao Zhang , Dianrong Xiu , Xiuwen Wang , Sha Guan , Qian Xu , Weiguo Su

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT02589821

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4111)

DOI

10.1200/JCO.2021.39.15_suppl.4111

Abstract #

4111

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Elisabeth De Vries

First Author: Chunmei Bai

First Author: Aaron Vinik

First Author: James C. Yao